MarketPulse
I

$IBRX

63 articles found
9 positive
52 negative
1 neutral
GlobeNewswire Inc.GlobeNewswire Inc.··Kahn Swick & Foti, Llc

Soleno Therapeutics Faces Securities Fraud Lawsuit Over Undisclosed DCCR Safety Risks

Soleno Therapeutics faces securities fraud lawsuit alleging undisclosed DCCR safety risks. Investors must file by May 5, 2026.
IBRXSMCISLNOsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Kahn Swick & Foti, Llc

ImmunityBio Faces Securities Fraud Class Action After FDA Warning, Stock Crashes 21%

ImmunityBio faces securities fraud lawsuit after FDA warns of false cancer cure claims for Anktiva, stock crashes 21% to $7.42.
IBRXsecurities fraudclass action lawsuit
BenzingaBenzinga··Erica Kollmann

Avis Surges 500% as Meme Stock Rally Reignites Short Squeeze Frenzy

Avis Budget Group surges 500% amid near-total short interest, reigniting meme stock mania. Heavily-shorted stocks like Beyond Meat and Navitas join rally despite weak fundamentals.
IBRXBYNDLCIDOPENOPENL+4short squeezeshort interest
GlobeNewswire Inc.GlobeNewswire Inc.··Levi & Korsinsky, Llp

ImmunityBio Hit With Securities Fraud Lawsuit Over Alleged Cancer Drug Misrepresentation

ImmunityBio faces securities fraud lawsuit after executive allegedly misrepresented ANKTIVA cancer drug capabilities; stock fell 21% following FDA Warning Letter.
IBRXsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Securities Class Actions Mount Against CIGL, FBRT, IBRX Over Alleged Fraud

Rosen Law Firm recruits lead plaintiffs in class actions against CIGL, FBRT, IBRX over alleged fraud; May 20, 2026 deadline critical.
FBRTFBRTpEIBRXYOOVsecurities class actionmisleading statements
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

ImmunityBio Securities Lawsuit Hits Critical Deadline as Claims Mount Over Anktiva Misstatements

ImmunityBio ($IBRX) investors face May 26, 2026 deadline to claim lead plaintiff status in securities lawsuit alleging false statements about Anktiva capabilities and business prospects.
IBRXsecurities class actionlead plaintiff deadline
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

ImmunityBio Investors Face May 26 Deadline in Securities Fraud Class Action

ImmunityBio investors have until May 26, 2026, to join securities fraud class action over allegedly false Anktiva claims.
IBRXsecurities class actionlead plaintiff deadline
GlobeNewswire Inc.GlobeNewswire Inc.··Portnoy Law Firm

ImmunityBio Faces Class Action After Failed Trial Triggers 12% Stock Plunge

Portnoy Law Firm launches class action against $IMNB following failed Phase 2 glioblastoma trial, citing investor losses from steep stock decline.
IBRXclass action lawsuitinvestor losses
GlobeNewswire Inc.GlobeNewswire Inc.··Kahn Swick & Foti, Llc

ImmunityBio Stock Plunges 21% After FDA Warning on Cancer Drug Claims

ImmunityBio faces securities fraud lawsuit following FDA warning letter about misleading Anktiva advertisements. Stock fell to $7.42; investors have until May 26 to file claims.
IBRXsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Securities Class Action Filed Against zSpace Over Alleged Misleading Disclosures

Rosen Law Firm investigates zSpace Inc. ($ZSPC) for allegedly misleading investor disclosures, preparing class action lawsuit seeking shareholder recovery.
IBRXHUBGZSPCsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Kessler Topaz Meltzer & Check, Llp

ImmunityBio Faces Securities Fraud Suit Over Anktiva Cancer Claims

ImmunityBio faces securities fraud lawsuit after FDA warning over false Anktiva claims. Stock plunged 21%. Investor deadline May 26, 2026.
IBRXsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Aquestive Investors Face Securities Deadline as Class Action Alleges Misleading Disclosures

Rosen Law Firm urges Aquestive Therapeutics investors to secure legal counsel before deadlines in securities class action alleging false product and disclosure statements.
FBRTFBRTpEIBRXAQSTsecurities class actionlead plaintiff deadline
GlobeNewswire Inc.GlobeNewswire Inc.··Hagens Berman

ImmunityBio Faces Major Securities Lawsuit Over FDA Warning on Drug Claims

ImmunityBio faces securities lawsuit after FDA warning letter regarding misleading efficacy claims for immunotherapy drug Anktiva, triggering 21% stock plunge.
IBRXinvestor lossessecurities class action
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Franklin BSP Realty Trust Faces Securities Lawsuit; Lead Plaintiff Deadline Set for April 2026

Rosen Law Firm files securities class action against Franklin BSP Realty Trust ($FBRT) over alleged misstatements on dividends; April 2026 deadline for lead plaintiff participation.
FBRTFBRTpEIBRXAQSTinvestor lossessecurities class action
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

ImmunityBio Investors Face May 26 Deadline in Securities Class Action Over Anktiva Claims

Rosen Law Firm urges $IBRX investors to join securities lawsuit alleging false statements about Anktiva capabilities. May 26, 2026 deadline looms for class action participation.
IBRXsecurities class actionlead plaintiff deadline
GlobeNewswire Inc.GlobeNewswire Inc.··The Schall Law Firm

ImmunityBio Securities Fraud Class Action Seeks Investors Amid Anktiva Claims

Schall Law Firm launches class action lawsuit against ImmunityBio for alleged securities fraud over false Anktiva drug statements between January-March 2026.
IBRXsecurities fraudclass action lawsuit
BenzingaBenzinga··Vandana Singh

ImmunityBio Surges on Strong Q1 Revenue, But FDA Warning Clouds Outlook

ImmunityBio stock rallied 7% after reporting $44.2M in Q1 product revenue, up 168% YoY, despite FDA warning over Anktiva marketing claims.
IBRXAnktivaImmunityBio
GlobeNewswire Inc.GlobeNewswire Inc.··Kahn Swick & Foti, Llc

ImmunityBio Faces Securities Fraud Suit After FDA Warning Triggers 21% Stock Plunge

ImmunityBio hit with securities fraud class action following FDA warning letter over misleading Anktiva cancer therapy ads. Stock fell 21% to $7.42.
IBRXsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Robbins Geller Rudman & Dowd Llp

Stellantis Faces Class Action Over Electrification Claims as Stock Plummets 23%

Class action lawsuit filed against $STLA for alleged misstatements on electrification prospects. February 2026 €22.2B reset triggered 23% stock decline; lead plaintiffs sought.
IBRXDRVNSTLAsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Rosen Law Firm Files Securities Class Action Against ImmunityBio Over Anktiva Claims

Rosen Law Firm files securities class action against ImmunityBio alleging false statements about Anktiva capabilities, recruiting lead plaintiffs.
PMIFBRTFBRTpEIBRXsecurities class actionlead plaintiff deadline